Announcement PDF ASX Announcement Enlitic, Inc. ARBN 672 254 027 1 23 April 2026 Annual General Meeting – Presentation and Addresses Enlitic, Inc. (ASX: ENL) (“the Company”) attaches a copy of the Chair address and presentation to be made at today’s Annual General Meeting of the Company. – ENDS – This announcement was authorised for release by the Board of Enlitic, Inc. Enquiries: Enlitic Investor Relations Australia: invest_au@enlitic.com About Enlitic Enlitic is a software company that uses artificial intelligence to develop software products that manage medical imaging data in radiology (such as MRI, CT scans, X-ray and ultrasound images) and licences such products to healthcare providers. Enlitic’s products (including its current product offering and product suite under development) seek to standardise, protect, integrate, and analyse data to create the foundation of a real-world evidence platform that can improve clinical workflows, increase efficiencies, and expand capacity. Read more at enlitic.com. Enlitic’s CDIs are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933 as amended, and in accordance with the procedures established pursuant to the provisions of a no action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this announcement. Read more at enlitic.com. Chairman’s Address At Enlitic, our focus is on transforming how healthcare organisations manage and derive value from their imaging data. The industry continues to face growing volumes of fragmented data, creating inefficiencies and limiting clinical impact. With our platform more established, we are enabling customers to better structure, connect and utilise their data, supporting more efficient workflows and improved patient outcomes. Over the past year, the Company consolidated operations following the acquisition of Laitek. This period centred on integration and alignment, with a clear focus on realising the strategic benefits of the combined businesses. Encouragingly, we have identified and have captured meaningful synergies, which has reduced our cost base and strengthened our operational platform from which to scale. Importantly, our strategy is delivering measurable progress. At the beginning of 2025, Enlitic had a single OEM relationship. Today, we have expanded this to multiple OEM partnerships, a clear sign of growing industry recognition of our technology and the value of our platform. While not all of these relationships have yet translated into revenue, they represent a potential pipeline of future opportunity and validate our go-to-market approach. The integration of Enlitic’s capabilities with Laitek’s data migration expertise is gaining traction with customers. Recent contracts and partnerships announced since the release of our 2025 Annual Report demonstrate increasing demand for a unified, end-to-end solution that addresses both data standardisation and migration challenges. Our platform is now more comprehensive, and we are seeing early signs that this integrated offering is resonating with customers. Notwithstanding this progress, we recognise that our share price performance has not met the expectations of the Board or our shareholders. The decline since the last AGM, alongside capital raisings undertaken during the year, has been challenging. These steps, however, were necessary to support the execution of our strategy and to position the Company for long-term growth. We have more work to do. The healthcare technology sector is complex, and the adoption of new solutions takes time. However, we are confident that our strategy is sound, our platform is more developed, and execution is now firmly underway. The expansion of our partner network and the growing commercial traction we are seeing clearly demonstrate that our approach is gaining momentum. As we move forward, the Board remains focused on disciplined execution, continued cost management, and converting our growing pipeline into sustainable revenue. We believe that the foundations laid over the past year position Enlitic to deliver long-term value for shareholders while continuing to support better outcomes for healthcare providers and their patients. 23 April 2026 Annual General Meeting ENLITIC, INC. AI DRIVEN DATA MANAGEMENT FOR THE MEDICAL IMAGING SECTOR Important Notice and Disclaimer This presentation has been prepared by Enlitic, Inc. (Enlitic or the Company) to provide summary information about the Company and its associated entities as at the date of this presentation, and the information in this presentation remains subject to change without notice. The Company has no obligation to update or correct this presentation. The presentation is for informational purposes only and is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or the law of any other jurisdiction. The information contained in this presentation does not constitute investment or financial product advice (nor taxation or legal advice) and is not intended to be used as the basis for making an investment decision. No representation or warranty, express or implied, is made as to the currency, accuracy, reliability, completeness or fairness of the information, opinions and conclusions contained in this presentation. None of the Company, its related bodies corporate (as defined in the Corporations Act), shareholders or affiliates, or any of their respective officers, directors, employees, affiliates, partners, representatives, consultants, agents or advisers (each a Limited Party) guarantees or makes any representations or warranties, express or implied, as to, or takes responsibility for, the currency, accuracy, reliability, completeness or fairness of this presentation or the information, opinions and conclusions contained in this presentation. The Company does not represent or warrant that this presentation is complete or that it contains all material information about the Company. To the maximum extent permitted by law, each Limited Party expressly disclaims any and all liability (whether direct, indirect, consequential or contingent), including, without limitation, any liability arising out of fault or negligence on the part of any person, for any expenses, damages, costs or loss arising from the use of information contained in this presentation or in relation to the accuracy or completeness of the information, statements, opinions or matters, express or implied, contained in, arising out of or derived from, or for omissions from, this presentation, including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom. None of the Company or any of the other Limited Parties act, or are responsible, as a fiduciary to you, your directors, officers, employees, affiliates, partners, representatives, consultants, agents, advisers, securityholders, creditors or any other person. You and each of the Company and the other Limited Parties expressly disclaim any fiduciary relationship. The Company and the other Limited Parties are relying on you complying with this important notice and disclaimer and on the truth and accuracy of the representations, warranties, undertakings and acknowledgments given by you. This presentation may contain certain forward-looking statements, forecasts, estimates, projections and comments about future events, including the Company’s beliefs, assumptions and expectations about the performance of its businesses and certain strategic transactions and the recovery of domestic and global airline booking levels. Forward looking statements can generally be identified by the use of forward-looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “goals”, “aims”, “target” and other similar expressions. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. Forward looking statements involve inherent risks and uncertainties, both general and specific, and there is a risk that such predictions, forecasts, projections and other forward-looking statements will not be achieved. A number of important factors, both known and unknown, could cause the Company’s actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements, and many of these factors are beyond the Company’s control. As such, there can be no assurance that actual outcomes will not differ materially from these statements. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and their differences may be material. Any forward-looking statements are provided as a general guide only and should not be relied on as an indication or guarantee of future performance. As such, no undue reliance should be placed on any forward-looking statement, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by the aftereffects of COVID-19 pandemic and certain geopolitical tensions. Past performance is not necessarily a guide to future performance, and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of any forward-looking statements or other forecast. Nothing contained in this presentation, or any other information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of the Company. None of the Company or any other Limited Party makes any representation or warranty as to the accuracy of any forward-looking statements contained in this presentation. Forward looking statements speak only as at the date of this presentation, and the Limited Parties disclaim any obligations or undertakings to release any update of, or revisions to, any forward-looking statements in this presentation. Financial information contained in this presentation (if any) is unaudited, unless otherwise stated, and is therefore subject to change. You should be aware that this presentation has been prepared at a time when the review of the financial information contained in the presentation has not been completed and, accordingly, the Company takes no responsibility for, and can provide no assurance as to the reliability of, any information relating to the financial condition and/or financial and operating performance of the Company. Recipients of this presentation are cautioned therefore to not place any reliance on the financial (or other) information included in the presentation. A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation. All dollar values are in Australian dollars (A$) unless otherwise stated. Certain market and industry data (including industry forecasts, projections, market sizes, market shares and market positions) included in this presentation has been obtained from public filings, research, surveys or studies conducted by third parties, including industry and general publications, which has not been independently verified by the Company, as well as from the Company’s own internal estimates and research. The Company cannot warrant or guarantee the adequacy, fairness, accuracy or completeness of such information. You should note that market data and statistics are inherently predictive and subject to uncertainty and not necessarily reflective of actual market conditions. There is no assurance that any of the industry or market forecasts, including management estimates, which are referred to in this presentation will be achieved. In addition, such data involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. In addition, while the Company believes its own estimates and research are reliable, such estimates and research have not been verified by any independent source. This presentation may contain trademarks and trade names of third parties, which are the property of their respective owners. Third party trademarks and trade names used in this presentation belong to the relevant owners and use is not intended to represent sponsorship, approval or association by or with the Company. OUR MISSION AGENDA Welcome & Chairman’s Address Formal Items of Business Resolutions & Questions Closure of Annual General Meeting CEO’s Presentation 2025 Highlights Recent Strategic Progress Growth Pathway & Outlook Q&A Lawrence Gozlan, Chairman Chairman’s Address 4 OUR MISSION BOARD AND EXECUTIVE MANAGEMENT Executive Management Board of Directors Lawrence B. Gozlan Board Chair Mr. Gozlan is the Chief Investment Officer and Founder of Scientia Capital and currently serves as a Director on several private and public company boards in Australia. Sergio Duchini Director Sergio drives strategy and growth with a strong focus on customer, innovation, M&A and corporate governance by leveraging his knowledge and experience in strategy development & implementation, accounting & finance, corporate structuring and M&A. Lisa Pettigrew Director Lisa has 25+ years experience in management consulting and technology services companies across multiple vertical industries, with a particular expertise in healthcare and life sciences. Michael Sistenich Director & Chief Executive Officer Michael has over 24 years of experience in the investment banking, corporate finance and asset management industry. Darren Scotti Chief Financial Officer and Company Secretary Darren is a veteran CFO and board member with over two decades of experience managing capital. Michael Sistenich Director & Chief Executive Officer Michael has over 24 years of experience in the investment banking, corporate finance and asset management industry. Industry Problems Radiology departments are experiencing workflow and capacity challenges compounded by a lack of data standardisation that impacts data quality and stakeholders within the enterprise. Staff within the radiology departments are experiencing high rates of stress and burnout resulting from increased workloads, increasing complexity of imaging studies and conflicting demands on time. Millions of studies encompassing petabytes of data must be moved with a low margin of error and meticulous management of migration timings to ensure patient wellbeing. Solution The Enlitic solution is built upon a software framework, creating a network between applications. It houses an ecosystem that enables and supports the exchange of information or content between different interdependent applications. The framework facilitates communications between modalities, Enlitic applications, Electronic Medical Records and PACS. It features a host of AI-powered applications that enable data standardisation, de-identification, anonymisation and workflow simplification. Our healthcare data migration solution significantly reduces costs and timelines by securely preserving non- essential studies. Our Mission Enlitic’s mission is to revolutionise healthcare by leveraging AI and data, empowering evidence-based decision-making, enhancing research, and transforming healthcare delivery. 6 Transforming Care with Data and Technology Empowering Complex Data Migration Innovation & Growth Value Creation Productivity Improvement Healthcare Providers 7 Michael Sistenich, CEO CEO Presentation 8 Enlitic is building the foundations for next-generation medical imaging by transforming how imaging data is managed, structured and utilized. We provide a comprehensive suite of data management solutions that enable healthcare providers and OEM partners to migrate, normalize, cleanse, structure, orchestrate, and enrich imaging data at scale. Our solutions seek to ensure that medical imaging archives are not only preserved but also transformed into interoperable, high-quality datasets that drive clinical, operational and research innovation. The Enlitic Platform includes: • Semperdata – a next generation AI-enabled medical imaging migration solution • Ensight Suite: • ENDEX Automated AI driven data normalization & workflows • ENABLE Medical Data Ops Management • ENCOG Data Anonymization & De-Identification Enlitic’s vision is to transform imaging data into a strategic foundation – empowering healthcare systems and industry partners to unlock efficiency, accelerate innovation, and ultimately improve patient care. AI ready data for Medical Imaging 20 25 Highlights Highlights GE Healthcare Start of GE relationship in 1Q25 & expansion in 4Q25 10 12% Reduction in Net Losses OEM Expansion Increased number of OEM relationships 1st Customer Contracts Migration & Data management offering 252% Increase in revenue from US$1.1m to US$3.8m ~US$2.5m Annualized savings through cost control & synergies US$2.84m Record total contract value wins in 4Q25 Empowering our Clients Philosophy • Leadership through domain expertise and workflow integration • End-to-End Capabilities; move, normalize, and orchestrate data • Simplify and streamline AI adoption Near-Term • Set the standard in AI-enabled migration and data normalization • Enhance existing data workflows • Turn the Data challenge into a strategic opportunity Mid-Term • Seamless AI Orchestration and embedded OEM AI workflow • Accelerate AI and GenAI adoption through better data 01 Trusted Data Foundation Provide a stable, governed data layer built for consistent, trustworthy decision making and automation 03 Vendor-Agnostic Ensight works across vendors, systems and environments with as a persistent, structured, and governed data layer 02 AI-Ready Architecture Automation-ready infrastructure that prepares clients and partners for the emerging era of Agentic AI 04 Workflows to Intelligence Powers operational workflows today while enabling AI-driven automation, analytics and intelligence for the future Delivering a foundational data layer Opportunity through technology 13 Referring Hospitals Referring Clinics Primary Hospital Teleradiology PACS Archive DICOM Medical imaging studies Ensight 2.0 Target Systems Data Migration Cost Savings M&A Activity Internal Upgrades Storage to cloud Target VNAs Target PACS Standardised, de-identified, anonymised DICOM Medical imaging studies Data ready for AI Automation 2026 14 Annotation / Labeling Search & Cohort Creation Procedure Code Inferencing De- identification Workflow Activation AI & Business Analytics Business Intelligence RWD & Research AI Validation & Creation Clinical / Operational Workflow Automation Billing / Coding Hanging Protocols ENDEX ENABLE SUITE Clinical Production Workflows z Raw Imaging Data AI Normalization Correct, Complete & Consistent Data From Strategy to Execution Real-World Deployment Transition from platform build to increasing real-world deployments Channel Expansion Increasing OEM relationships and in market integrations with key vendors Repeatable Execution Moving past proof-of-concepts to repeatable execution Positioned for Scale Positioned for scale across customers and partners Commercial Momentum Record commercial progress • US$2.84m of New Contract TCV signed in 4Q25 • 1Q26 expected to exceed 4Q25 with US$3.52m in total contract value secured during period • Growth across both Direct and OEM Channels OEM relationships & Ecosystem continue to expand • 8 Global OEMs now actively engaged with Migrations and Data Management offering • OEMs driving global reach and repeatability • New engagements increasingly interested in solutions beyond Migrations 16 Engaging leading healthcare institutions • Increasing client interest in combined Migrations and Data Management Solutions • Validation through increasing customer wins: Penn Medicine, St Jude Childrens, Parkland Health • Increasing number of clients across all geographies; North America, Europe and Asia Pacific Summary & Outlook Building the data foundation for Medical Imaging Positioned at the intersection of Data, AI and Clinical Workflows Transition from being a migration provider to a data infrastructure platform Financials Outlook • Record US$2.84m of new contract revenue in 4Q25. • 1Q26 new contracts to exceed 4Q25 with total contract value generated of US$3.52m • Continued focus on efficiency and reduction to the cost base • Continued progress towards achieving operational cash flow break even target 17 Questions 18